Trade AbbVie ^ABBV

AbbVie Inc. $ABBV Stock Acquired by Artemis Investment Management LLP

AbbVie Inc. $ABBV Stock Position Increased by Toth Financial Advisory Corp - Stock Observer

AbbVie (NYSE:ABBV) Price Target Raised to $290.00

Biotech Stocks At 52-Week Highs - ABBV On FDA Designations, HSTM, OGN

8,817 AbbVie Inc. $ABBV Shares Bought by Congress Asset Management Co.

AbbVie (NYSE:ABBV) Issues Q3 2026 Earnings Guidance - Stock Observer

AbbVie (NYSE:ABBV) Stock Price Expected to Rise, Scotiabank Analyst Says

Biotech Stocks To Keep An Eye On - October 6th - Markets Daily

3 'Strong Buy' Dividend Aristocrat Stocks on Analysts' Watch List

Johnson & Johnson (JNJ) Is Becoming a Growth Stock. Does AbbVie (ABBV) Make JNJ Look Expensive?

AbbVie (NYSE:ABBV) Stock Price Up 1.8% Following Analyst Upgrade

Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets

2,008 AbbVie Inc. $ABBV Shares Sold by Canandaigua National Bank & Trust Co. - Stock Observer

5,659 AbbVie Inc. $ABBV Shares Sold by MRA Advisory Group

American National Bank & Trust Reduces Stake in AbbVie Inc. $ABBV

AbbVie's Temab-A Earns FDA Breakthrough Therapy Designations In CRC, NSCLC;Stock Up

AbbVie's Telisotuzumab Adizutecan Secures Dual FDA Breakthrough Therapy Designations

AbbVie (NYSE:ABBV) Hits New 12-Month High on Analyst Upgrade - Stock Observer

Genmab (CPSE:GMAB) Posts Two Strong Trial Readouts, Is The Valuation Now Too Hard To Ignore?

AbbVie (ABBV) Cut Frontline DLBCL Progression Or Death Risk By 51%

AbbVie (ABBV) Pays Out More Than It Earns. How Long Can That Hold?

AbbVie Stocks Edge Higher as Lymphoma Trial Cuts Progression Risk 51%

Forget Bonds: How Retirees Collect $6,650 a Month From Dividends Alone

AbbVie Inc. $ABBV Stock Sold by Hall Laurie J Trustee - Daily Political

Prediction: LLY Has Another Massive Growth Opportunity Beyond Weight Loss

Abbvie-Genmab Epkinly data signal first-line filing for DLBCL

Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms

Scotiabank Forecasts Strong Price Appreciation for AbbVie (NYSE:ABBV) Stock

$100,000 in 5 Dividend Kings Will Generate Close to $4,000 Each Year Safely

AbbVie Rewarded Patient Investors but Punished Those Who Bought on Good News

AbbVie (NYSE:ABBV) Releases Q3 2026 Earnings Guidance

Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug | Morningstar

Genmab and AbbVie's Epcoritamab Treatment Significantly Reduces Blood Cancer Progression Risk, ETPharma

AbbVie Inc. (ABBV) Stock: Phase 3 Lymphoma Trial Cuts Progression Risk 51%

AbbVie (NYSE:ABBV) Stock Price Up 1.2% - Still a Buy?

Genmab stock surges 11% on positive cancer drug trial data

Park National Corp OH Sells 6,771 Shares of AbbVie Inc. $ABBV

AbbVie Inc. $ABBV Position Lowered by Eastern Bank

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

AbbVie (NYSE:ABBV) Stock Jumps 1.2% - Still a Buy? - Daily Political

AbbVie Inc. $ABBV Stock Position Lessened by MassMutual Private Wealth & Trust FSB

Best Pharmaceutical Stocks To Add to Your Watchlist - October 4th - Stock Observer

Is AbbVie (ABBV) Still Undervalued On FDA Approval And Fresh Pipeline Data?

AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?

Pharmaceutical Stocks To Watch Now - October 3rd - Zolmax

5 High-Yield Dividend Stocks to Buy for October Income with Cash Flow to Spare

AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think.

Biotech Stocks To Watch Now - October 2nd - Daily Political

Eli Lilly (LLY) and AbbVie (ABBV) Are Expanding Their Pipelines. Their Valuations Tell Two Different Stories

AbbVie (NYSE:ABBV) Stock Jumps 1.3% - Here's What Happened

How Much Does a 58-Year-Old Need Invested to Replace a $160,000 Salary With Dividends?

CX Institutional Cuts Stock Position in AbbVie Inc. $ABBV - Daily Political

Biotech Stocks To Watch Now - October 2nd - Zolmax

Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: safety, mechanistic insights, and an exploratory signal in del(17p) disease

RINVOQ Drives Continued Skin Repigmentation Through Week 76 In AbbVie Studies

HRSA discloses manufacturers approved for revised 340B rebate pilot

5 Solid Dividend Stocks to Buy Now

AbbVie to Host Third-Quarter 2026 Earnings Conference Call | Morningstar

5 High-Yield Dividend Stocks That Pass the Coverage Test (Not Just the Yield Test)

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

What Does AbbVie (ABBV) Need To Prove After Its Eczema Drug And AI Update?

AbbVie To Present New Dermatology Data At 2026 EADV Congress

Drug Repurposing Market - Global Strategic Business Report: Forecasts Growth to $37.3Billion by 2030, Profiling AbbVie, AstraZeneca, Pfizer, Novartis & Johnson & Johnson

AbbVie Inc. (ABBV) Stock: Rebounds as Zumilokibart Shows Strong Skin and Itch Improvement Results

BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength

AbbVie Reports Positive Phase 2 Results For Zumilokibart In Atopic Dermatitis

AbbVIe's Zumilokibart Meets Phase 2 Goal In Atopic Dermatitis Study

AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 | Morningstar

AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress | Morningstar

AbbVie (NYSE:ABBV) Shares Down 1% - Should You Sell?

AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval

AbbVie Partners With Valkai To Advance AI-powered Clinical Research

Allergan Aesthetics receives Health Canada authorization for Boey® (trenibotulinumtoxinE), the first and only rapid-onset, short-duration neurotoxin for frown lines

AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development

AbbVie Inc. (NYSE:ABBV) Receives Average Recommendation of "Moderate Buy" from Analysts

FDA Nod For JUVMO Parkinson's Drug Could Be A Game Changer For AbbVie (ABBV)

Is AbbVie (ABBV) A Bargain After FDA Approval Of JUVMO For Parkinson's?

Best Pharmaceutical Stocks To Follow Now - September 26th - Daily Political

Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial

Should FDA Approval Require Action From AbbVie (ABBV) Investors?

Johnson & Johnson's Next Growth Engine Is Taking Shape

AbbVie Wins FDA Approval For JUVMO In Parkinson's Disease

Kodiak soars on double phase III win in wet AMD

AbbVie Won FDA Approval for Parkinson's Pill Juvmo. Here's Why Management Already Expects a Slow Start

AbbVie lands FDA approval for next-generation Parkinson's drug, Juvmo

AbbVie (ABBV) Stock: FDA Greenlights Innovative Parkinson's Treatment Juvmo - Blockonomi

AbbVie Gets FDA OK of Juvmo for Parkinson's Disease | Morningstar

AbbVie Announces FDA Approval Of JUVMO For Parkinson's Disease

US FDA approves AbbVie's drug for Parkinson's disease

Abbvie's Juvmo FDA approval brings new Parkinson's option | BioWorld

International practice patterns and beliefs concerning intravenous methylprednisolone and low-dose aspirin in giant cell arteritis

AI Could Give AbbVie (ABBV) a New Route to Long-Term Pipeline Growth